Drug Utilization Review Board
Minutes
Draft

Name of Meeting: Drug Utilization Review Board
Date of Meeting: November 20, 2014
Length of Meeting: 2 hour and 4 minutes
Location of Meeting: DMAS Board Room 13th Floor

Members Present:
Randy Ferrance, MD, Chair
Avtar Dhillon, MD
Seth Brant, MD
Bill Rock, PharmD
Wendy Nash, PharmD
Cynthia Fagan, FNP
Sandra Dawson, RPh

Members Not Present:
Rhonda Bass, MD
Michelle Thomas, PharmD
Jonathan Evans, MD

DMAS Attendees:
Rachel Cain, PharmD
Donna Proffitt, RPh, Pharmacy Program Manager
Bryan Tomlinson, Health Care Services Division Director
Danielle Adeeb
Tyrone Wall
Kim Richardson

Contractors:
Donna Johnson, PharmD, Clinical Pharmacy Manager, Xerox
Tina Carter, CPhT, Pharmacy Technician

Vendors:
Debbie Moody, RPh, Magellan Health Services

Visitors:
Richard Lomax, Purdue
Dave Condrick, Pharmacyclics
Jason Richardson, Actavis
John Smith, Merck
Emily Holmes, KB
Rick Meidlinger, Janssen
Michelle Jacobs, Otsuka
Christopher Fields, Lundbeck
Paula Kupresak, AbbVie
Dennis D'Amico, Janssen
Rob Houk, Chiesi
Lisa Pompa, Vertex
Jonell Lanta, Shire
Katelyn Nguyen, VAH
Mark Stephan, Alkermes

Call to Order and Introductions
Dr. Ferrance called the meeting to order at 2:06pm.

Minutes—August 21, 2014
Dr. Ferrance asked if there were any changes or additions to the minutes from the August 21, 2014 meeting. The motion was made and seconded for the meeting minutes to be approved with no changes.

New Drugs
Cerdelga® (eliglustat) – Dr. Johnson presented DUR and Service Authorization (SA) criteria. The motion was made to accept the DUR criteria as written with the addition of "prolonged QT interval" to the DUR drug-disease (MC) criteria as severity level 2. The motion was made to accept the SA criteria with the following editorial changes to the SA criteria: if patient is an ultra-extensive metabolizer or indeterminate metabolizer then deny the SA request. The motions were seconded and approved by the Board.

Jardiance® (empagliflozin) – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Kerydin™ (tavaborole) – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written; the Board seconded and approved the criteria.

Northera™ (droxidopa) – Dr. Johnson presented the DUR and Service Authorization (SA) criteria. The motion was made to accept the criteria as written with the following additions to the SA form: patient must have a one week trial of each of the other hypotensive agents (midodrine, fludrocortisone and pyridostigmine) and extend the length of evaluation period to 3 months. The Board seconded and approved the criteria and SA form.

Sublingual Immunotherapy for Allergies
Oralair®, Grastek® and Ragwitek™ – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written with the addition of beta-blockers, alpha-blockers and ergot alkyloids as drug-drug interactions and Oralair and Grastek as therapeutic duplicates. The Board seconded and approved the criteria.

Striverdi® Respimat® (olodaterol) – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Triumeq® (abacavir, dolutegravir, lamivudine) – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Zydelig® (idelalisib) – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written. The Board seconded and approved the criteria.

Service Authorizations

Dr. Johnson reported that Elelyso, approved for the treatment of Type 1 Gaucher Disease, gained FDA approval for pediatric patients ages 4 years and older. The current SA criteria will be updated to include this expanded age group.

Reports

ProDUR and RetroDUR –Dr. Johnson reviewed the reports provided in the DUR Board binder. A request was made to start adding Criteria to the RetroDUR reports.

Utilization Analysis Reports – Dr. Johnson reviewed the top 25 Drugs Ranked by Claim Count, by Payment Amount and the Cost of Utilization Analysis by Drug Type.

Top Diagnoses by Age – Dr. Johnson reviewed the top Diagnoses by Age for all ages.

AAP Report

Dr. Johnson reviewed the report provided in the DUR Board binder. A request was made to prepare a run chart to identify patterns.

Future Topics

Metabolic Monitoring in Patients on Atypical Antipsychotics – *in process*
Analysis of Compounded Medications to review ingredients – requires further research after today's discussion.

1. Identify all ingredients in Baclofen compounds
2. Identify any other pharmacies and pull all ingredients for Cubicin
3. Look at Hydromorphone compound (expensive one)
4. Pull evidence and discuss appropriateness for Ketamine
5. Pull evidence and discuss appropriateness for Oxytocin

Other Business

Bryan Tomlinson shared that DMAS had mailed a plaque recognizing Jane Settle's, NP, Vice Chair years of service to the Commonwealth and DUR Board. Ms. Settle retired from the VCU Medical Center last fall and resigned her position on the DUR Board.

Bryan Tomlinson reported on the Governor's 10-Step plan to expand services. One step is the Governor's Access Plan (GAP) for the seriously mentally ill (SMI). It is estimated that there are over 20,000 individuals with SMI not currently enrolled in Medicaid. These individuals will be enrolled in the fee-for-service Medicaid program (FFS) not managed Medicaid. The program will begin 01/01/2015. Mr.

Tomlinson also suggested that the DUR Board monitor the drug utilization for this population.

Rachel Cain shared with the Board that DMAS will begin utilizing the First Data Bank (FDB) Clinical Modules for prospective DUR edits sometime in the 1st quarter 2015.

The meeting was adjourned at 4:10 pm.

Future DUR Board Meetings scheduled for 2015 (February 19, May 21, August 20, and November 19)